(Q52839795)

English

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

scientific article published on 15 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

1 reference

based on heuristic

inferred from title

20

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

author name string

Pippa G Corrie

1

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Andrea Marshall

2

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Janet A Dunn

3

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Mark R Middleton

4

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Paul D Nathan

5

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Martin Gore

6

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Neville Davidson

7

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Steve Nicholson

8

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Charles G Kelly

9

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Maria Marples

10

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Sarah J Danson

11

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Ernest Marshall

12

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Stephen J Houston

13

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Ruth E Board

14

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Ashita M Waterston

15

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Jenny P Nobes

16

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Mark Harries

17

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Satish Kumar

18

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Gemma Young

19

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

publication date

15 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

15

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

6

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

620-630

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis inhibitors: current strategies and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced expression of vascular endothelial growth factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunomodulatory effects of anti-angiogenic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of immunity by antiangiogenic molecules in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970110-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70110-X

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/24745696

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52839795&oldid=1417676397"